Cencora (COR) Q3 FY26 earnings call

Cencora delivered strong Q3 FY26 results, driven by robust specialty pharmaceutical performance, particularly within its MSO platforms, and effective capital deployment. The company raised its full-year adjusted EPS guidance, reflecting confidence in its pharmaceutical-centric strategy and continued execution, despite headwinds from manufacturer list price reductions. Management remains focused on digital transformation and talent development to sustain long-term growth.